Sant Pau study reveals lung destruction mechanisms in fatal COVID-19
SARS-CoV-2 Transformation of Lung Tissue in Fatal COVID-19 Cases
SARS-CoV-2 transforms a healthy lung into scarred, non-functional tissue in the most severe cases of COVID-19, according to a study published by researchers at the Sant Pau Research Institute in collaboration with hospitals in Madrid and Sweden, EL PAÍS reported. Until now, the clinical consequences of fatal bilateral pneumonia were well documented, but the exact cellular mechanisms driving the destruction remained unknown.
Key Clinical Takeaways:
- Spatial transcriptomics reveals a progressive collapse of the oxygen-exchange barrier, characterized by the disappearance of AT1 cells and blood vessels alongside an explosive increase in peribronchial fibroblasts.
- Natural killer cells, representing the primary antiviral defense, decline steadily as the infection worsens, while a specific molecular pathway drives pulmonary fibrosis.
- Researchers suggest that existing antifibrotic medications like pirfenidone and nintedanib could be evaluated in preclinical models to halt this specific scarring process.
Spatial Mapping of the Collapse
The research team examined lung samples from 19 patients who died from COVID-19 and compared them against healthy control lungs. Rather than homogenizing the tissue and losing spatial context, the investigators utilized spatial transcriptomics. This technology preserves tissue architecture while displaying active genes at precise cellular locations, functioning like a street-by-street map rather than a blurred overview.
The analysis showed a progressive breakdown of the pulmonary system responsible for transferring oxygen from air into the bloodstream. Cells forming the delicate exchange barrier and their accompanying micro-vessels systematically disappear. Simultaneously, immune cells and scar-forming cells invade the tissue. Peribronchial fibroblasts multiply rapidly during the acute phase, advancing across the organ and permanently reducing respiratory capacity as normal lung architecture disintegrates.
Altered Repair Mechanisms Drive Lung Fibrosis
Throughout this destructive process, resident stem cell-like populations known as AT2 cells attempt to regenerate the lost oxygen-exchanging AT1 cells. However, this repair mechanism remains incomplete or altered in severe cases, explaining why certain patients fail to achieve full pulmonary recovery. Concurrently, natural killer cells decrease steadily as the pathology advances.
Investigators identified a molecular pathway acting as the primary engine of fibrosis, stiffening the lung tissue until it becomes entirely unusable, alongside the deactivation of a regulatory braking pathway. Manel Esteller, who leads the investigation, explained to EL PAÍS that this specific fibrotic cascade occurs exclusively in COVID-19 and differs fundamentally from conventional pneumonia or chronic obstructive pulmonary disease.
Antifibrotic Medications Offer Potential for Rapid Evaluation
These findings point toward potential interventions using existing or experimental drugs for severe cases and future pandemic threats. Approved antifibrotic medications such as pirfenidone and nintedanib, alongside molecules designed to block the identified scarring pathway, offer immediate candidates for evaluation. Esteller noted that preclinical models should test whether these compounds produce the hypothesized protective effects on lung tissue.
Because many of these candidate therapies already possess established safety profiles in humans, they could theoretically undergo rapid evaluation through drug repositioning. While COVID-19 no longer presents the widespread public health emergency seen earlier in the pandemic, the virus continues to cause severe disease among vulnerable and elderly populations.
Researchers also noted a potential molecular link between severe pulmonary injury and an Alzheimer’s-associated protein, a connection that may hold relevance for persistent symptoms like brain fog, though investigators emphasize that this hypothesis remains speculative.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.